Immuno-Oncology | Specialty

Durvalumab Approaches EU Approval for Locally Advanced PD-L1+ NSCLC

July 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy and whose tumors express PD-L1 on ≥1% of tumor cells.

Immunotherapy Requires Precision Medicine Approach for NSCLC

July 27th 2018

Immunotherapy should be given as a tailored, not blanket, treatment approach, especially for patients with lung cancer, according to Giorgio Scagliotti, MD, PhD.

Dr. Lynch on the Immuno-Oncology Network at Bristol-Myers Squibb

July 27th 2018

Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses the Immuno-Oncology (IO) Network at Bristol-Myers Squibb.

Dr. Bauml on Emerging Biomarkers in NSCLC

July 27th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses emerging biomarkers in non–small cell lung cancer (NSCLC).

Dr. Konstantinopoulos on Rationale for TOPACIO Trial in Ovarian Cancer

July 25th 2018

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the rationale behind the TOPACIO trial for the treatment of patients with recurrent ovarian cancer.

Dr. Nghiem on Immunotherapy in Merkel Cell Carcinoma

July 25th 2018

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses immunotherapy for the treatment of Merkel cell carcinoma.

Frontline Pembrolizumab Improves Survival in HNSCC

July 25th 2018

Pembrolizumab (Keytruda) significantly improved overall survival compared with the standard frontline regimen of cetuximab (Erbitux) plus platinum chemotherapy and 5-FU in patients with recurrent or metastatic HNSCC.

Targeted Therapies Emerging for Less-Common NSCLC Subtypes

July 25th 2018

Jessica Bauman, MD, addresses current and emerging therapeutic options for patients with BRAF, ROS1, and RET abnormalities in non–small cell lung cancer.

Biomarkers for Frontline Immunotherapy Pose Obstacles in NSCLC

July 25th 2018

John A. Kosteva, MD, discusses the adoption of immunotherapy into the treatment paradigm for patients with non–small cell lung cancer.

Dr. Weber Discusses Updated Data for CheckMate-238

July 24th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses updated data for the Checkmate-238 trial.

Langer Highlights the Impact of Chemoimmunotherapy in NSCLC

July 24th 2018

Although impressive single-agent data have been seen with agents such as pembrolizumab (Keytruda) versus chemotherapy in a high–PD-L1 population, the combination of PD-L1 inhibitors and chemotherapy may prove to be beneficial in a broader group of patients.

Dr. Reardon on Pembrolizumab and Bevacizumab for Glioblastoma

July 23rd 2018

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses pembrolizumab (Keytruda) and bevacizumab (Avastin) for the treatment of patients with recurrent PD-L1–positive glioblastoma.

Dr. Agarwala on Impact of Combining Entinostat with Pembrolizumab

July 20th 2018

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of combining entinostat with pembrolizumab (Keytruda) across a number of tumor types.

Novel Combinations Advance Through RCC Pipeline

July 20th 2018

Peter J. Van Veldhuizen, MD, discusses available and emerging therapies for patients with kidney cancer.

Atezolizumab Regimen Extends PFS in Frontline Nonsquamous NSCLC

July 19th 2018

Adding atezolizumab to pemetrexed and cisplatin or carboplatin in the frontline setting reduced the risk of disease progression or death versus chemotherapy alone in patients with advanced nonsquamous non–small cell lung cancer, according to findings from the phase III IMpower132 study.

Dr. Tolaney on Abemaciclib Plus Pembrolizumab for HR+, HER2- Breast Cancer

July 18th 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the phase Ib results of abemaciclib (Verzenio) plus pembrolizumab (Keytruda) for hormone receptor-positive, HER2-negative metastatic breast cancer.

Ramalingam Reflects on Recent Advances in SCLC

July 17th 2018

Suresh A. Ramalingam, MD, reflects on recent data in small cell lung cancer and what is on the horizon in the landscape.

Dr. West Discusses Latest Immunotherapy Findings in Lung Cancer

July 17th 2018

H. Jack West, MD, medical director of thoracic oncology, Swedish Cancer Institute of Swedish Medical Center, discusses the latest immunotherapy findings for lung cancer treatment.

Pembrolizumab Data Reviewed in Classical Hodgkin Lymphoma

July 15th 2018

George F. Geils, Jr, MD, discussed the clinical efficacy and adverse event management techniques for pembrolizumab as a treatment for patients with classical Hodgkin lymphoma.

Galsky Discusses Ongoing Combination Immunotherapy Trials in Bladder Cancer

July 13th 2018

Matthew Galsky, MD, discusses the IMvigor130 and CheckMate-901 studies, as well as the future for chemotherapy in bladder cancer.